I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
[Updated, 7/27/15, 7:35pm. See below.] After a battle with Alzheimer’s disease, audio engineering pioneer Ray Dolby died in 2013. Now his family is using the fortune he left behind... Read more »
The FDA has approved alirocumab (Praluent), a drug that gives people who aren’t helped enough by statins a new option to lower their cholesterol and fight heart disease. How many people... Read more »
[Corrected 7/27/15, 1.49pm. See below.] Spun out of its namesake two years ago, vaccine maker SutroVax has reeled in a $22 million Series A round to push forward a... Read more »
Biotechs everywhere are going public these days. You might have heard.
Approaching the traditional market lull in August, we’re up to nearly 40 life science IPOs in 2015, by my own... Read more »
Once again, the big West Coast news of the week came from an East Coast company, Celgene, making it rain. (That’s a figure of speech, unfortunately. Out here, rain would be... Read more »
Protagonist Therapeutics thinks it has solved a biological riddle, and several investors are shelling out $40 million to help test the company’s solution in humans for the first time before the... Read more »
They employ doctors, prescribe tests, and for $2,000 a year they’ll help you keep on top of your health, but they don’t diagnose illnesses. That’s the line new Seattle health startup... Read more »
The U.S. House of Representatives took a big step this morning toward major changes in the federal government’s relationship to biomedical research, funding, and regulation. The chamber passed the 21st Century... Read more »
Juno Therapeutics has built remarkable momentum—including last week’s much-dissected $1 billion deal with Celgene—upon early success treating leukemia and lymphoma patients with a first generation of experimental T cell therapies developed... Read more »
With an important clinical trial underway, South San Francisco, CA-based Global Blood Therapeutics hopes to join the ranks of public biotech companies. It has filed for an IPO worth as much... Read more »
[Corrected 7/8/15, 3:48pm. See below.] Some people who’ve made it big in biotech drive fast cars. Some take outlandish vacations. Some don’t take any vacations at all. (I’m sure... Read more »
It was a short work week leading up to the 4th of July, but it was long on news out West. There were plenty of fireworks of the legal, political, and... Read more »
Natera of San Carlos, CA, has bumped the fundraising goal for its upcoming IPO to $175 million, according to a document filed today with the Securities and Exchange Commission. The maker... Read more »
If you’re an investor anticipating the potential $100 million-plus IPO of microbiome company Seres Therapeutics, your wait should be over before the weekend comes. If you’re a patient with a terrible... Read more »
By now you’ve had a day or two to meet Exome, Xconomy’s new place for all things life sciences, health, and biotech, which launched Monday. Let me amend that. Some things... Read more »
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.